Oral Polio Vaccine Response in the MAL-ED Birth Cohort Study: Considerations for Polio Eradication Strategies
Overview
Authors
Affiliations
Background: Immunization programs have leveraged decades of research to maximize oral polio vaccine (OPV) response. Moving toward global poliovirus eradication, the WHO recommended phased OPV-to-IPV replacement on schedules in 2012. Using the MAL-ED prospective birth cohort data, we evaluated the influence of early life exposures impacting OPV immunization by measuring OPV response for serotypes 1 and 3.
Methods: Polio neutralizing antibody assays were conducted at 7 and 15 months of age for serotypes 1 and 3. Analyses were conducted on children receiving ≥3 OPV doses (n = 1449). History of vaccination, feeding patterns, physical growth, home environment, diarrhea, enteropathogen detection, and gut inflammation were examined as risk factors for non-response [Log(titer) < 3] and Log(titer) by serotype using multivariate regression.
Findings: Serotype 1 seroconversion was significantly higher than serotype 3 (96.6% vs. 89.6%, 15 months). Model results indicate serotypes 1 and 3 failure was minimized following four and six OPV doses, respectively; however, enteropathogen detection and poor socioeconomic conditions attenuated response in both serotypes. At three months of age, bacterial detection in stool reduced serotype 1 and 3 Log titers by 0.34 (95% CI 0.14-0.54) and 0.53 (95% CI 0.29-0.77), respectively, and increased odds of serotype 3 failure by 3.0 (95% CI 1.6-5.8). Our socioeconomic index, consisting of Water, Assets, Maternal education, and Income (WAMI), was associated with a 0.79 (95% CI 0.15-1.43) and 1.23 (95% CI 0.34-2.12) higher serotype 1 and 3 Log titer, respectively, and a 0.04 (95% CI 0.002-0.40) lower odds of serotype 3 failure. Introduction of solids, transferrin receptor, and underweight were differentially associated with serotype response. Other factors, including diarrheal frequency and breastfeeding practices, were not associated with OPV response.
Interpretation: Under real-world conditions, improved vaccination coverage and socio-environmental conditions, and reducing early life bacterial exposures are key to improving OPV response and should inform polio eradication strategies.
Geographic disparities impacting oral vaccine performance: Observations and future directions.
Burke R, Ramani S, Lynch J, Cooper L, Cho H, Bandyopadhyay A Clin Exp Immunol. 2025; 219(1).
PMID: 39774633 PMC: 11773816. DOI: 10.1093/cei/uxae124.
A highly immunogenic UVC inactivated Sabin based polio vaccine.
Tobin G, Tobin J, Wiggins T, Bushnell R, Kozar A, Maale M NPJ Vaccines. 2024; 9(1):217.
PMID: 39543143 PMC: 11564903. DOI: 10.1038/s41541-024-00995-w.
Effects of Iron Status on Adaptive Immunity and Vaccine Efficacy: A Review.
Stoffel N, Drakesmith H Adv Nutr. 2024; 15(6):100238.
PMID: 38729263 PMC: 11251406. DOI: 10.1016/j.advnut.2024.100238.
Mwamba G, Nzaji M, Hoff N, Mukadi P, Musene K, Gerber S J Multidiscip Healthc. 2024; 17:1219-1229.
PMID: 38524863 PMC: 10960541. DOI: 10.2147/JMDH.S437351.
Vaccine and malnutrition: A narrative review.
Tripathy S, Das S, Malik A J Family Med Prim Care. 2023; 12(9):1808-1813.
PMID: 38024923 PMC: 10657100. DOI: 10.4103/jfmpc.jfmpc_596_23.